查找临床试验

已按「阵发性睡眠性血红蛋白尿」检索,对应国际通用词 paroxysmal nocturnal hemoglobinuria

试验不在中国怎么办?

共找到 12 项正在招募的试验(在欧美日韩等发达国家设有中心)

数据更新于 11:18,每 5 分钟自动同步
正在招募不适用NCT07457151

Danicopan PMS in Korea

South Korea

年龄 不限不限

AstraZeneca

正在招募III 期NCT07154745

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

Brazil、Canada、Italy、Poland、South Korea 等 7 国

年龄 18 Years不限

Regeneron Pharmaceuticals

正在招募III 期NCT05744921

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Canada、Colombia、Hungary、India、Italy 等 12 国

年龄 18 Years不限

Regeneron Pharmaceuticals

正在招募不适用NCT06524726

The International PNH Interest Group PNH Registry

United States

年龄 不限不限

International PNH Interest Group

正在招募I 期 / II 期NCT05876312

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Australia、United Kingdom

年龄 18 Years不限

ADARx Pharmaceuticals, Inc.

正在招募不适用NCT05755867

Global PNH Patient Registry

United States

年龄 不限不限

Aplastic Anemia and MDS International Foundation

正在招募I 期 / II 期NCT07187401

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Canada、South Korea、United Kingdom

年龄 18 Years不限

Regeneron Pharmaceuticals

正在招募II 期NCT06412497

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

United States

年龄 0 Years75 Years

Masonic Cancer Center, University of Minnesota

正在招募III 期NCT06934967

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

United States、Brazil、Colombia、Germany、Italy 等 6 国

年龄 2 Years18 Years

Novartis Pharmaceuticals

正在招募III 期NCT06449001

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Canada、France、United Kingdom

年龄 12 Years17 Years

Alexion Pharmaceuticals, Inc.

正在招募不适用NCT06411626

Home Reported Outcomes in PNH

United States

年龄 18 Years99 Years

Novartis Pharmaceuticals

正在招募不适用NCT07416162

A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

South Korea

年龄 18 Years99 Years

Novartis Pharmaceuticals